相似文献
1
Adjuvant aromatase inhibitors: are we there yet?
Cancer. 2003 Nov 1;98(9):1779-81. doi: 10.1002/cncr.11746.
2
Letrozole in breast cancer.
N Engl J Med. 2004 Feb 12;350(7):727-30; author reply 727-30.
3
[Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
Suppl Tumori. 2004 Jul-Aug;3(4):S27-31.
4
[Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Suppl Tumori. 2004 Jul-Aug;3(4):S25-6.
5
Aromatase inhibitors--a triumph of translational oncology.
N Engl J Med. 2005 Dec 29;353(26):2807-9. doi: 10.1056/NEJMe058273.
6
Aromatase inhibitors continue their ATAC on tamoxifen.
Trends Mol Med. 2002;8(4 Suppl):S12-3. doi: 10.1016/s1471-4914(02)02304-3.
7
[Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Gynakol Geburtshilfliche Rundsch. 2005 Jun;45(3):143-6. doi: 10.1159/000085195.
8
[The ATAC study on adjuvants in breast cancer].
Suppl Tumori. 2004 Jul-Aug;3(4):S15.
9
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Cancer. 2004 Oct 1;101(7):1482-9. doi: 10.1002/cncr.20522.
10
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Anticancer Drugs. 2008 Mar;19 Suppl 2:S1. doi: 10.1097/01.cad.0000277610.08129.06.
Zotero 插件